Navigation Links
Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis

OWL Genomics, biotechnological company, has presented at the CIC bioGUNE hold at the Bizkaia Technological Park (Derio), the first DNA chip concerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal, steatosis and NASH predisposed subjects.

Non alcoholic steatohepatitis is a progressive disease of the liver of unknown etiology, characterized histologically by fatty acid accumulation, hepatocyte damage and inflammation resembling alcoholic hepatitis. NASH is a critical stage in the process that spans from hepatic steatosis to cirrhosis and hepatocarcinoma. NASH is one of the most common causes of elevated aminotransfereases in patients referred for evaluation to hepatologists. Obesity and type-2 diabetes are associated to NASH. Since the prevalence of these diseases is increasing, the prevalence of NASH is also expected to increase and therefore, this disease has become an emerging public issue in United States as well as in other developed countries

The HEPATOCHIP presented at the mentioned forum, has been developed in collaboration with the Hepatology Services of the Clinic Hospital in Barcelona and Príncipe de Asturias Hospital in Alcalá de Henares (Madrid). This chip analyses the co-expression of 85 genes that are related with NASH and is about to be validated in collaboration with the Hepatology Service of Gregorio Marañón Hospital (Madrid).

This HEPATOCHIP method determines the co-expression of genes in the liver tissue sample, providing monitoring treatment regimens to check progression/regression of these liver pathologies.

This HEPATOCHIP can be used as a prognostic tool for NASH-predisposed patients, to make possible more finely tuned diagnosis of this disease and allow healthcare professionals to tailor treatment to individual patients' needs. This chip also assess the efficacy of non-alcoholic steatohepatitis treatment by determining progression or regression of NAS H in patients before, during, and NASH treatment.

###

OWL Genomics, a biotech company focused on providing leading-edge applications in human health with innovative and pioneer technologies within the international scientific community, provides the first product in early diagnosis and therapeutic targets in hepatic diseases.

OWL Genomics is devoted to research into the diagnosis and prevention of liver diseases, through the combination of its state-of-the-art technology and experienced and dedicated personnel.


'"/>

Source:OwlGenomics


Related biology news :

1. New comparative toxicogenomics database
2. Measuring the impact of post-genomics on Mediterranean populations
3. Enlisting genomics to understand flu evolution
4. Drawing with DNA: Bioart illuminates genomics
5. Study reveals genomics of inflammation from severe injury
6. NIH launches comprehensive effort to explore cancer genomics
7. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
8. Ticks, flukes, and genomics: Emerging pathogens revealed
9. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
10. Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
11. Large-scale genomics project will hunt genes behind common childhood diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
Breaking Biology News(10 mins):
(Date:3/20/2017)... Yorba Linda, CA (PRWEB) , ... March 20, ... ... interference and require expensive and laborious sample preparation methods in order to reduce ... is often underappreciated outside of the area of elemental analysis. , This ...
(Date:3/20/2017)... ... 20, 2017 , ... The fourth annual Hackaday Prize , which aims ... impact on peoples’ lives, launches today. Sponsored by Digi-Key and Microchip ... thousands in cash prizes to engineers, inventors and tinkerers who “build something that matters.” ...
(Date:3/20/2017)... , ... March 20, 2017 , ... ... HEPARIN calibration verification / linearity test kit has received US FDA 510(k) clearance ... VALIDATE® HEPARIN kit evaluates Heparin Anti-Xa activity in a human plasma matrix. ...
(Date:3/20/2017)... , March 20, 2017  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of the BioAmber Inc. ("BioAmber" or the "Company") (NYSE: ... information and assist the investigation by visiting the firm,s site: ... BioAmber and certain of its officers and/or directors have violated ... 1934. ...
Breaking Biology Technology: